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This overview addresses the recent research developments in the role of tumour-associated macrophages
(TAM) in bone metastasis biology and management of breast and prostate cancer as well as in primary
and lung metastatic osteosarcoma. Immunosuppressive M2-type TAMs have been shown to associate
with poor prognosis. Throughout their life cycle, macrophages (Macs) can adapt to environmental cues
and inﬂuence the surroundings by secreting different cytokines and enzymes crucial to matrix re-
modelling, infection ﬁghting, immune regulation and/or inﬂammation. In general terms, there is a broad
and complex spectrum of Mac polarization statuses from M1 (classically activated/inﬂammatory) to M2
(alternatively activated/wound healing/immune regulating) Macs. Often the activation status of TAMs
resembles more the M2-type. Considering the physiological functions of M2 Macs, it is no surprise that
TAMs appear to have a role in metastasis, participating in almost every step of the metastatic cascade,
which we review and explore in selected bone tropic cancers.
& 2016 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Macrophages, osteomacs and osteoclasts
Macrophages (Macs) are immune cells derived both from em-
bryonic precursors and circulating CD14þ monocytes which origi-
nate from the bone marrow [1]. Cell fate mapping studies in mice on
adult microglia, bone marrow cells, alveolar macrophages and mac-
rophages in mouse inﬂammation [2] have further demonstrated that
tissue resident Macs can proliferate in situ, thereby bypassing the
need of differentiation from newly recruited monocytes. Macs adopt
different polarization/activation statuses as response to environ-
mental stimuli and perform distinct physiologic functions from
phagocytosis to antigen presenting, wound healing, immune reg-
ulation, tissue vascularization and inﬂammation [3]. Mac polarization
spans a broad spectrum of intermediate statuses, with M1 or clas-
sically activated Macs at one extreme and M2 or alternatively acti-
vated Macs at the other extreme [4,5]. Human M2 Macs can be
further classiﬁed as M2a, M2b and M2c (Fig. 1), the third being the
most immunosuppressive Mac type. Recently, for in vitro differ-
entiated macrophages, a nomenclature that clearly identiﬁes the
differentiation and activation stimuli used (e.g., M(IFN-γ), M(IL-4), M
(IL-10), M(IFN-γþLPS), etc.) has been proposed [1].
Bone marrow resident Macs (Osteomacs) are located in canopy-
like structures in endosteal and periosteal surfaces, above osteo-
blasts [6]; osteoclasts result from the fusion of several myeloidGmbH. This is an open access art
f Medicine, Kiinamyllynkatu
.osteoclast precursors [7]. Osteomacs constitute approximately 17%
of the bone marrow cells and they differ from osteoclasts by the
expression of F4/80 and CD68. In addition, osteomacs play an
important role in bone repair and hematopoietic stem cell (HSC)
niche maintenance [6].2. Tumour-associated macrophages (TAMs) in the bone meta-
static cascade
In primary breast tumours, 5–40% of the tumour mass consists
of TAMs [9]. TAMs often resemble M2 Macs and the majority of the
published studies report an association between poor disease
outcome and the number of TAMs or low M1/M2 ratio [8]. In some
studies, TAMs are associated with good prognosis (e.g., prostate,
stomach, colon, cervix, lung and pancreas). However, the M1/M2
ratio or the location of the TAMs might - at least to some extent -
explain these favourable outcomes [8].
In order to form bone metastases the cancer cells have to go
through several steps, the so-called metastatic cascade. The me-
tastatic cascade includes local invasion of surrounding healthy
tissue, intravasation (formation of circulating tumour cells, CTCs),
migration and survival in circulation, extravasation (formation of
disseminated tumour cells, DTCs), angio- and lymphangiogenesis,
matrix remodelling, premetastatic niche formation, survival at the
new site either as dormant or proliferating DTCs, dormancy es-
cape, proliferation and macrometastases formation [10]. We and
others have recently reviewed the role of TAMs in each of the
metastatic steps [11–13].icle under the CC BY-NC-ND license
Fig. 1. Human macrophage (Mac) polarization. Polarizing cytokines, surface mar-
kers, secreted factors and physiologic functions.
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evidence from preclinical and clinical studies
The majority of preclinical and clinical studies assess TAMs in
primary tumours and metastasis-associated macrophages (MAMs)
in visceral metastases (e.g. lung, liver, kidney, spleen, brain). Some
preclinical models require long progression times to form bone
metastases which might limit their usefulness due to ethical rea-
sons. Nevertheless, there is some indirect evidence of a role for
TAMs in bone metastasis arising from studies in cancer models
with systemic (Csf1op/op mice), conditional (MaFIA mouse model)
or pharmacological macrophage ablation (e.g., the use of clo-
dronate liposomes, CLO-LIP) and from retrospective clinical stu-
dies (see Table 1).
3.1. TAMs in breast cancer bone metastasis
Primary breast cancer cells express a plethora of cytokines and
growth factors into the local microenvironment and circulation.
Amongst those factors, macrophage recruiting and differentiating
factors such as VCAM-1 (vascular cell adhesion protein-1), M-CSF
(macrophage colony-stimulating factor also known as CSF-1-col-
ony stimulating factor-1) and MCP-1 (monocyte chemotactic pro-
tein-1) have been characterized. Additionally, breast cancer cells
have been shown to set the scene for distant metastases (pre-
metastatic niche formation) long before actual CTC arrival to theTable 1
Clinical studies of TAM inﬁltration and polarization status in cancer types known to ha
Total TAMs M2 M1 n Main conclusions
Breast cancer
CD68 – – 1322 Association with other poor prognostic mar
CD68 CD163 144 CD163þTAMs in tumour stroma positively c
correlated with ERþ CD68 in tumour strom
survival
CD68 CD163 HLA-DRα 562 CD163þTAMs associated with other poor pr
4tumour size) in the Cox multivariate mod
Prostate cancer
CD68 – – 100 4TAMs density,↑Hexim1 expression,↑SMAD
disease
Osteosarcoma
CD14 CD163 HLA-DRα 145 Association of CD14þTAMs with ↑OS, metast
associations of M1 or M2 TAMs with progno
↑survival (Macs’ subtype analysis was perfor
Abbreviations: OS, overall survival; ER, oestrogen receptor; PR, progesterone recep
macrophagespotential metastatic site [14]. Among others, factors such as S100
proteins, MMPs (matrix metalloproteinases), VEGFs (vascular en-
dothelial growth factors), ﬁbronectin [14], and lysyl oxidase (LOX)
[15] are crucial for the premetastatic niche formation. These fac-
tors elicit matrix remodelling at the new site, recruit bone marrow
derived cells (e.g., Macs) and provide “trails” (chemotaxis of CTCs
by the secreted products) and “foot-holds” (premetastic niche ex-
pression of integrins and adhesion molecules) for colonization of
the new site by DTCs.
The best described axes of crosstalk between breast cancer cell
and TAM to date are the CSF-1 (cancer cell derived) CSF1R (TAM
expressed) axis and the EGF (epidermal growth factor, TAM derived)
and EGFR (EGF receptor, cancer cell expressed) axis. They are both
known to have implications on early metastatic cascade steps of
breast cancer cells such as cancer cell-TAM co-migration, invasion
and intravasation [16]. A recent work has found that FLT1 expression
(also known as VEGFR1) on MAMs is essential for CTC seeding of
lungs and persistent metastatic growth, with no effect on primary
tumour invasion and intravasation. FLT1þmacrophages were found
to be substantially enriched in human breast cancer metastatic sites
when compared with primary tumour sites. In mouse models of
breast cancer lung metastasis, FLT1 was exclusively expressed by
MAMs and not by monocytic precursor cells. These murine MAMs
were shown to resemble tumour promoting TAMs. FLT1 inhibition
decreased lung metastatic index without affecting MAM recruit-
ment, but rather altering the inﬂammatory gene signature of MAMs.
This included downregulation of CSF-1 expression through focal
adhesion kinase 1 (FAK1) signalling [17]. The interaction between
tumour cells, macrophages and endothelial cells (the so called tu-
mour microenvironment of metastasis, TMEM) is essential to es-
tablish a spatially and temporally transient hyperpermeable tumour
vasculature, which allows “streams” of tumour cells and TAMs to
intravasate and disseminate. This study has shown that the macro-
phages at the TMEM are a subset of TAMs with high Tie2 and VEGFA
expression [18].
Most of the early events described above translate into lung or
liver metastases. However, recent studies [15] have shown bone
premetastic and metastatic results, with some indirect proof of
Mac involvement. The latter study with intratibial and orthotopic
MDA-MB-231 models showed that silencing the EGFR expression
in the cancer cells decreased bone and mammary fat pad tumour
growth, and reduced the production of M-CSF and MMP-9 in the
tumours [19]. Studies in murine breast adenocarcinoma models,
where M-CSF blockade was applied, demonstrated a decrease in
TAM inﬁltration and subsequent delay in angiogenesis [20]. Fur-
thermore, M-CSFR blockade decreased lung metastasis in theve bone involvement.
Reference
kers (4grade, ER-, PR- and 4proliferation) [9]
orrelated with 4grade,4tumour size, Ki67þ , ER-, PR-, and inversely
a was an independent prognostic factor for ↓breast cancer speciﬁc
[30]
ognosis markers (4grade, ER-, node positivity,4proliferation and
el for RFS
[31]
2 expression, and mild SMAD7 expression play important roles in the [32]
asis suppression in high-grade patients and ↑microvessel density. No
sis. Possible role for balanced M1/M2 TAMs response leading to
med in a sub-cohort of n¼29)
[33]
tor;TAM, tumour-associated macrophage; RFS, recurrence free survival; Macs,
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cancer M-CSF/M-CSFR blockade decreased TAM inﬁltration and
reprogrammed the remaining TAMs to support antigen presenta-
tion and T-cell activation [22]. Although no TAM analysis was
provided, it is reasonable to speculate that the reduced M-CSF and
MMP-9 levels in the MDA-MB231 models reﬂected decreased TAM
inﬁltration and decreased M2 Mac polarization. Thus, the observed
decrease in bone and primary tumour growth of the MDA-MB231
model can be a combination of cancer cell, TAM and other mi-
croenvironmental effects [19]. Lysyl oxidase (LOX) secreted by
hypoxic breast tumour cells accumulates in premetastatic niches
where it crosslinks collagen IV at the basement membrane. This
favours lung premetastatic niche formation in the 4T1 and MDA-
MB231 models by enhancing metastatic tumour cell invasion and
bone marrow derived cells’ recruitment to premetastatic lungs
which further enhances matrix remodelling by Mac secreted
MMPs [23]. A study on premetastatic bone lesions done with in-
tracardiacaly injected LOX silenced 4T1 cells demonstrated a role
for LOX in osteoblast inhibition and osteoclastogenesis activation
which favoured tumour cell colonization of bone [15]. It is again
reasonable to think that LOX would also affect osteomacs and
TAMs in the primary and bone metastasis sites, but further studies
are required to elucidate that.
3.2. TAMs in prostate cancer bone metastasis
Prostate cancer bone metastases are often osteoblastic or
mixed osteoblastic/osteolytic lesions. Rodent models of prostate
cancer have revealed similar TAM associations with early steps of
the metastatic cascade as seen for breast cancer with perhaps a
more predominant proangiogenic component [11]. Additionally, a
study using the intratibial PC-3 mouse model of tumour growth in
bone has shown that cancer cell derived IL-6 recruited Macs to the
tumour site and promoted tumour aggressiveness, whereas Mac
depletion or IL-6 silencing decreased the size of bone lesions, the
degree of bone lysis and the incidence of lymph node metastases
[24]. This is in line with the ﬁndings by Bonapace and colleagues
[25] in breast cancer lung metastatic models, where IL-6 produc-
tion by pulmonary recruited inﬂammatory Macs of tumour bear-
ing mice increased VEGF-A signalling which subsequently un-
leashed lung metastasis after anti-CCL2 treatment cessation [25].
More recently, the RM-1 and PC-3 prostate cancer models were
established in macrophage deﬁcient mouse models (the inducible
macrophage deﬁcient Csf1op/op model, the macrophage ablation
model MaFIA and the CLO-LIP Mac depleted model) [26]. In these
models, primary tumour growth was impaired in Mac depleted
mice compared to controls with normal Mac numbers. Tumour-
bearing bones of control mice had larger numbers of Macs than
tumour-free bones. However, the Mac and bone tumour growth
association held true in the Mac depleted models suggesting that
osteomacs and TAMs may have a role in supporting also the
prostate cancer bone lesion formation [26]. Studies performed in
TRAMP and TRAMP-PSA models indicate a more complex scenario,
showing a mixed M1/M2 Mac polarization of TAMs. In vivo Mac
depletion increased tumour growth, suggesting an anti-tumour
role for TAMs in the early stages of these prostate cancer models
[27]. This perhaps reﬂects a predominant M1 polarization of TAMs.
Based on the protein expression data, mostly only M1 markers (IL-
1β and TNF-α) were signiﬁcantly elevated in TAMs compared with
peritoneal Macs with the exception of IL-10 an M2 marker [27].
Although the authors claim that TAM polarization is mixed M1/M2
and base it on mRNA relative expression data of M1 and M2
markers [27], this is questionable as it may not fully reﬂect TAMs
polarization and function which can only be assessed by surface
markers and protein expression/secretion analysis.3.3. TAMs in osteosarcoma
The role of osteoclasts and TAMs in osteosarcoma and osteo-
sarcoma metastasis is often confounded, probably due to the re-
levance and closeness of both cell types in this cancer type [28].
A recent study recurring to ex vivo and in vivo techniques has
demonstrated that IL-34 and M-CSF are expressed by osteosarco-
ma cells, and IL-34 overexpression contributes to tumour growth
and lung metastasis by recruiting M2 Macs and by increasing neo-
angiogenesis [29]. Clinical data supporting these preclinical results
on the role of TAMs in osteosarcoma is provided in Table 1.4. TAM targeting therapeutic opportunities
Considering every TAM/bone metastasis aspect discussed so far,
it is clear that TAMs like many other cells of the tumour micro-
environment are almost ideal therapeutic targets, as they are ge-
netically stable, seem to adopt a different polarization in cancer
compared to the physiological polarization status in a given tissue,
and are recruited and educated by cancer cell secreted factors.
Thus, agents targeting recruitment and polarization (e.g., anti-M-
CSF antibodies and small molecule inhibitors of M-CSFR and bi-
sphosphonates), M1 activating agents (e.g. mifamurtide, IL-2, zo-
ledronate), agents interfering with the cancer cell/TAM crosstalk
(e.g., VCAM-1/α4 integrin inhibition) and Mac depleting agents
(e.g., CLO-LIP) are all strategies being pursued, mostly still in the
preclinical setting [11]. However, with the ever evolving under-
standing of the roles of TAMs, it is reasonable to think that in the
future TAM modulating therapies might be at the disposal of
clinicians and patients.5. Outstanding questions1. What is the origin of TAMs? Are TAMs derived from resident
Macs educated by the growing mass of dormancy escaped
DTCs? Are TAMs educated by the premetastatic niche factors
elicited by primary tumour cells’ remote signalling? Or are
TAMs newly recruited monocytes locally differentiated by si-
milar players?
2. Do TAMs co-migrate with CTCs?
3. Are osteomacs prone to similar re-education by DTCs, pre-
metastatic niche and primary tumour factors, potentially be-
coming metastases-associated macrophages (MAMs)?
4. Are TAMs involved in the CTC to DTC transition, by means other
than facilitating extravasation of CTCs?
5. Are TAMs involved in the dormancy escape of DTCs? Which are
the triggers for this phenomenon?
6. Does the immunological status of each particular breast, pros-
tate and other bone seeking cancer patient predispose him/her
to develop bone metastases?
7. What are the other immune and microenvironmental players
affected by TAMs further contributing for a worse prognosis?
8. Is TAM targeting/re-education a real therapeutic option to bone
metastatic patients?Conﬂict of interest
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